STOCK TITAN

VYNE Therapeutics Inc. - VYNE STOCK NEWS

Welcome to our dedicated page for VYNE Therapeutics news (Ticker: VYNE), a resource for investors and traders seeking the latest updates and insights on VYNE Therapeutics stock.

VYNE Therapeutics Inc. (Nasdaq: VYNE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for dermatological and immuno-inflammatory conditions. Headquartered in Bridgewater, New Jersey, the company was founded in 2003 and initially known as Menlo Therapeutics Inc. before rebranding to VYNE Therapeutics Inc. in September 2020.

VYNE's portfolio includes AMZEEQ, a topical minocycline foam approved for treating inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. Another key product is ZILXI, which has shown efficacy in managing acne vulgaris. Additionally, VYNE is developing FMX103, presently in Phase III clinical trials aimed at treating moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam in Phase II trials for moderate-to-severe acne vulgaris.

Expanding its focus, VYNE is advancing the development of serlopitant, a once-daily oral NK1 receptor antagonist, as a treatment for pruritus associated with prurigo nodularis. The company is also innovating in the immuno-inflammatory space with its InhiBET™ platform, featuring advanced product candidates like VYN202 and VYN201. VYN202, an oral small molecule BD2-selective BET inhibitor, has demonstrated promising preclinical results for psoriasis and rheumatoid arthritis. VYN201, designed for local administration, is targeting nonsegmental vitiligo and has shown positive Phase 1b clinical trial results.

Recent developments highlight VYNE's commitment to advancing its pipeline, including the initiation of a Phase 2b trial for VYN201 in vitiligo and clearance of the Investigational New Drug (IND) application by the FDA for VYN202, paving the way for its first-in-human studies.

Rhea-AI Summary
VYNE Therapeutics Inc. has successfully closed a private placement financing, raising $88.2 million. The company sold 10,652,543 shares of common stock at a purchase price of $2.245 per share and issued pre-funded warrants to certain investors. The PIPE was priced to meet Nasdaq listing rules. VYNE plans to use the funds to support its BET inhibitor programs until the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
none
-
Rhea-AI Summary
VYNE Therapeutics announced positive preclinical data for its oral small molecule BD2-selective BET inhibitor, VYN202, in models of psoriasis and rheumatoid arthritis. VYN202 demonstrated significant inhibition of key inflammatory cytokines and showed efficacy comparable to another inhibitor. The company plans to initiate Phase 1a and Phase 1b trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.39%
Tags
none
-
Rhea-AI Summary
VYNE Therapeutics has signed a securities purchase agreement with healthcare-focused institutional investors for a private placement financing, resulting in gross proceeds of $88 million. The financing will fund VYNE's clinical development programs for VYN201 and VYN202 through the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.39%
Tags
none
Rhea-AI Summary
VYNE Therapeutics Inc. announced positive data from its Phase 1b trial evaluating once-daily dosing of VYN201 in patients with nonsegmental vitiligo. The trial showed a statistically significant dose-dependent reduction in the F-VASI score from baseline for the 1.0% and 2.0% cohorts compared to the 0.5% cohort. VYN201 was well-tolerated with no clinically relevant adverse events. The results suggest that VYN201 has the potential to be a category leader in the treatment of vitiligo. VYNE plans to initiate a Phase 2b clinical trial in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.39%
Tags
-
Rhea-AI Summary
VYNE Therapeutics to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences
-
Rhea-AI Summary
VYNE Therapeutics Inc. announced financial results for Q2 2023 and provided a business update. They are making progress in developing their small molecule BET inhibitors, VYN201 and VYN202, for immuno-inflammatory conditions. Phase 1b data for VYN201 in vitiligo patients will be announced in Q3 2023. IND-enabling studies for VYN202 are ongoing, with an IND submission expected by year-end. The company had a net loss of $10.1 million for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.27%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.52%
Tags
-
Rhea-AI Summary
VYNE Therapeutics has selected VYN202 as its development candidate for the treatment of immuno-inflammatory conditions. VYN202 has shown promising results in preclinical studies and is designed to be more selective and safer than previous inhibitors. IND-enabling studies are underway, with an IND submission expected by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.83%
Tags
none
Rhea-AI Summary

VYNE Therapeutics has announced promising preclinical data on its novel pan-BET inhibitor, VYN201, for treating idiopathic pulmonary fibrosis (IPF). VYN201 demonstrated significant reductions in lung fibrosis and hydroxyproline levels compared to placebo. Specifically, at doses of 0.5 mg/ml and 1 mg/ml, VYN201 achieved a 65.8% reduction in lung fibrosis scores and an 8.8% improvement in blood oxygen saturation. The treatment also led to a 51.8% increase in functional lung volume. These results support the potential broad utility of VYN201 as a locally-administered anti-inflammatory and anti-fibrotic therapy. VYNE is currently evaluating VYN201 in a Phase 1b study for non-segmental vitiligo, seeking to further validate its safety and efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
42.49%
Tags

FAQ

What is the current stock price of VYNE Therapeutics (VYNE)?

The current stock price of VYNE Therapeutics (VYNE) is $2.5 as of December 20, 2024.

What is the market cap of VYNE Therapeutics (VYNE)?

The market cap of VYNE Therapeutics (VYNE) is approximately 35.3M.

What does VYNE Therapeutics Inc. specialize in?

VYNE Therapeutics Inc. specializes in developing and commercializing innovative therapies for dermatological and immuno-inflammatory conditions.

What are some key products of VYNE Therapeutics Inc.?

Key products include AMZEEQ, a topical minocycline foam for acne, and ZILXI. VYNE is also developing FMX103 for rosacea, FCD105 for acne, and serlopitant for prurigo nodularis.

What recent advancements has VYNE Therapeutics Inc. made?

Recent advancements include positive preclinical data for VYN202, initiation of Phase 2b trials for VYN201 in vitiligo, and FDA clearance for VYN202’s IND application.

Where is VYNE Therapeutics Inc. headquartered?

VYNE Therapeutics Inc. is headquartered in Bridgewater, New Jersey.

What is the InhiBET™ platform?

The InhiBET™ platform features proprietary bromodomain and extra-terminal domain (BET) inhibitors, including VYN201 and VYN202, targeting immuno-inflammatory conditions.

What is AMZEEQ used to treat?

AMZEEQ is used to treat inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older.

How does VYNE contribute to the treatment of vitiligo?

VYNE is developing VYN201, a locally-administered BET inhibitor, which has shown promising results in clinical trials for nonsegmental vitiligo.

What are BET inhibitors?

BET inhibitors block pro-inflammatory cytokine transcription and have potential in treating immuno-inflammatory and fibrotic diseases. VYNE’s BET inhibitors include VYN201 and VYN202.

What phase is VYN202 currently in?

VYN202 is progressing to Phase 1a single ascending dose/multiple ascending dose (SAD/MAD) trials in healthy volunteers.

How can investors stay updated on VYNE Therapeutics Inc.?

Investors can stay updated through VYNE’s website, press releases, SEC filings, public conference calls, and webcasts.

VYNE Therapeutics Inc.

Nasdaq:VYNE

VYNE Rankings

VYNE Stock Data

35.26M
13.38M
8.43%
51.92%
0.69%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRIDGEWATER